-
134 - I'm puzzled by an ad on the cover of a specialist journal, announcing that a product is now availabile in Canada. There are no other claims or description of the product, other than suggesting the physician call the pharma company for more information or samples. I'm puzzled becuase the ad has no balance copy, no warnings, and has not been PAABed; there is no prescribing information. The company must feel that the ad falls out of the scope of the PAAB Code, but i don't see any of the exemptions applying. Plus, launch is a time when MDs are particularly in need of info regarding safety information. The masthead says that all drug ads have been cleared by PAAB, but this is clearly not the case. Is there something I am missing?
• Jennifer Carroll -
132 - A variation to question #89. An international speaker has been asked to make a presentation to a Canadian meeting of healthcare professionals about a product which has recently received its NOC. Her talk is not accredited, or about the disease category, but is focussed on the product itself which is mentioned by brand name. The slides, which are not printed out for distribution at the meeting but used onscreen, are prepared by the speaker and not by the sponsor. Do the slides require PAAB preclearance?
• Jennifer Carroll -
120 - We are considering producing a patient brochure in an alternate language other than french or english that remains valid until mid 2010 by PAAB. I understand that PAAB does not require a review if this is simply a translation and printing however in the last two months the Merck logos and trademarks have changed. If we change the trademarks/logos on this brochure do we require an additional review seeing as we are only changing the logos to reflect the new company name and then printing this new language which would have the same mid 2010 expiry date. Content of the brochure will not be changed.
• Jennifer Carroll -
112 - As a private clinic we are planning to prepare advertising material to be played on TV only to the patients waiting in the waiting area. The contents of these ads will be prepared by specialists in different medical disciplines. This will mostly contain OTC, NHP products. Is this activity subject to PAAB review?
• Jennifer Carroll -
105 - Je travaille pour une agence de publicité et nous devons préparer un lancement de produit pour un produit pharmaceutique en vente libre, sous restriction, behind the counter (annexe II). J'aimerais svp avoir les réglèments publicitaires à respecter pour chacune des provinces.
• Jennifer Carroll -
103 - If we have a non-branded poster, talking about a disease and with a call to action: talk to your doctor. This poster will be given to the secretary of the doctor's office by the pharmaceutical representative and then will be posted in the examining room. Is this subject to PAAB review? Also with the poster there will be a booklet disease oriented for patients also to be given to secretary to be left in the examining room. Is this subject to PAAB review? With that poster there will be a card to be given to the patient by the doctor with the same message and a call to action (talk to your doctor) is this also subject to PAAB review?
• Jennifer Carroll -
102 - Can a pharmaceutical company provide ,upon request from a Third party HCP controlled website, a company produced educational slide deck ( disease and treatment) that has not been reviewed and approved by PAAB.The third party website wishes to provide these educational slide kits to their members as self learning resources.
• Jennifer Carroll -
89 - Would a live event whereby healthcare professionals are invited to hear key opinion leaders discuss unmet need in a therapeutic area and a drug that has just obtained NOC be deemed subject to preapproval by PAAB? The live events would be sponsored by the pharma company whose drug has just obtained NOC. The purpose would be to inform prescribers of the approved indications and appropriate clinical usage. The program would not be accredited.
• Jennifer Carroll -
87 - We are producing a directory of canadian clinics that offer a specific test. There will be an introduction outlining why the test is important, how it is done etc. The booklet will be sponsored by a drug company (corporate logos will be on the cover) but there is nothing in it that mentions their or any other company's drug products (and they have no affiliation with the tests, clinics or instruments used). The booklet will be distributed by the sponsors reps as a service. Healthcare providers will offer independent review of the content. Does this require PAAB review?
• Jennifer Carroll -
85 - Could you please confirm for me whether or not a Dear Doctor letter outlining a Nursing Assessment program needs PAAB approval. The program is being run by a 3rd-party. The letter does not contain any information about product and it outlines the parameters of the program itself (i.e. # of patients needed to be recruited, length of day, etc.) The Dear Doctor letter is being left with the doctor and it is being delivered and signed by the representative.
• Jennifer Carroll -
81 - Mon client doit faire une pièce visuelle descriptive de son produit qui sera remise aux professionnels qui l'utilisent, soit les médecins et les technologues. Le produit se nomme SmartVent et c'est un système de délivrance radioaérosol qui permet la production d'imagerie de ventilation pulmonaire. Je ne suis pas certaine si cette publicité doit être envoyée à PAAB pour approbation car c'est un 'medical device'. J'aimerais être certaine des règlements pour ce genre de produit.
• Jennifer Carroll -
72 - In order for a prescription to be filled for product X, the doctor must submit a form which will function as the prescription to a 3rd party distributor. the form also includes the patient's signature which allows the patient to request the 3rd party company to research the patient's insurance coverage for product x on their behalf. There are no product claims on the form (no efficacy, no safety, nothing). Only the doctor receives the form (the patient can not get it any other way then when the doctor makes the decision to Rx the drug for the patient). The drug is restricted to a very specific indication; therefore the form includes the specific diagnosis code to allow the 3rd party to ensure that the drug is no prescribed off label. The form is a strictly administrative document, the pharma company never has access to any of the specific information (no doctor names, no patient names etc...). Am I correct in my conclusion that this would not need PAAB review?
• Jennifer Carroll -
71 - As per 6.6d and the exemption of "now on provincial formulary", does this apply to a change in formulary status? As an example "Product Y has a new formulary status". This is of course would not be linked to a therapeutic message but is intended to inform the audience of a change in formulary status. Would such a mention be PAAB exempt?
• Jennifer Carroll